ZPredicta specializes in advanced drug development technologies that utilize organ-specific 3D culture models to closely mimic the human tumor microenvironment. Their innovative platform integrates both cellular and extracellular components, allowing for a more accurate representation of how therapeutic agents interact with tumors in a real human context. This comprehensive approach not only preserves the critical interactions between tumors and their surrounding tissues but also facilitates the evaluation of drug efficacy, mechanisms of drug resistance, and off-target toxicity. By recreating the complex architecture of human organs, ZPredicta's models demonstrate a high correlation with clinical outcomes, significantly enhancing the predictive power of preclinical drug testing.

The technology employed by ZPredicta is designed to address the high failure rate of anticancer drugs in clinical trials, which often occurs due to the inadequacy of traditional 2D models. Their patient-derived 3D culture platform supports the long-term maintenance of both malignant and non-malignant cells, ensuring that the cellular composition reflects the native conditions of human disease. This platform is fully customizable, accommodating various tissue types, drug classes, and analytical methods, making it a versatile tool for drug candidate screening, biomarker discovery, and the rescue of failed drug candidates. By simulating the intricate dynamics of the tumor microenvironment, ZPredicta aims to improve the success rate of anticancer therapies and ultimately enhance patient outcomes.

United States

Ixchel Scientific (now zPREDICTA) is creating organ-specific 3D technologies to reconstruct human biology and eliminate guesswork from drug development. 

Our patient-Derived 3-D Culture™ (PD-3D™) platform incorporates both cellular and extracellular elements of tissue microenvironment recapitulating the major steps of tumor development under physiological conditions. Our products include organ-specific extracellular matrices and PD-3D™ tissue culture kits that capture the multistep nature of cancer progression. Our partners have access to a variety of discovery and preclinical services to assist in drug development efforts.

ZPredicta

Company Details